Bliss GVS Pharma Limited

NSEI:BLISSGVS Stock Report

Market Cap: ₹16.5b

Bliss GVS Pharma Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Gagan Sharma

Chief executive officer

₹21.6m

Total compensation

CEO salary percentage100.0%
CEO tenure3.7yrs
CEO ownershipn/a
Management average tenure3.7yrs
Board average tenure6.8yrs

Recent management updates

Increases to Bliss GVS Pharma Limited's (NSE:BLISSGVS) CEO Compensation Might Cool off for now

Jul 19
Increases to Bliss GVS Pharma Limited's (NSE:BLISSGVS) CEO Compensation Might Cool off for now

Recent updates

Is Bliss GVS Pharma (NSE:BLISSGVS) A Risky Investment?

Dec 15
Is Bliss GVS Pharma (NSE:BLISSGVS) A Risky Investment?

Investors Don't See Light At End Of Bliss GVS Pharma Limited's (NSE:BLISSGVS) Tunnel

Nov 23
Investors Don't See Light At End Of Bliss GVS Pharma Limited's (NSE:BLISSGVS) Tunnel

Here's Why Bliss GVS Pharma (NSE:BLISSGVS) Has Caught The Eye Of Investors

Oct 26
Here's Why Bliss GVS Pharma (NSE:BLISSGVS) Has Caught The Eye Of Investors

These 4 Measures Indicate That Bliss GVS Pharma (NSE:BLISSGVS) Is Using Debt Safely

Aug 25
These 4 Measures Indicate That Bliss GVS Pharma (NSE:BLISSGVS) Is Using Debt Safely

Bliss GVS Pharma Limited's (NSE:BLISSGVS) Prospects Need A Boost To Lift Shares

Aug 07
Bliss GVS Pharma Limited's (NSE:BLISSGVS) Prospects Need A Boost To Lift Shares

Increases to Bliss GVS Pharma Limited's (NSE:BLISSGVS) CEO Compensation Might Cool off for now

Jul 19
Increases to Bliss GVS Pharma Limited's (NSE:BLISSGVS) CEO Compensation Might Cool off for now

Bliss GVS Pharma's (NSE:BLISSGVS) Dividend Will Be ₹0.50

Jul 18
Bliss GVS Pharma's (NSE:BLISSGVS) Dividend Will Be ₹0.50

Bliss GVS Pharma (NSE:BLISSGVS) Is Due To Pay A Dividend Of ₹0.50

Jul 04
Bliss GVS Pharma (NSE:BLISSGVS) Is Due To Pay A Dividend Of ₹0.50

We Think Bliss GVS Pharma's (NSE:BLISSGVS) Solid Earnings Are Understated

May 10
We Think Bliss GVS Pharma's (NSE:BLISSGVS) Solid Earnings Are Understated

Bliss GVS Pharma Limited's (NSE:BLISSGVS) Price Is Right But Growth Is Lacking

Apr 27
Bliss GVS Pharma Limited's (NSE:BLISSGVS) Price Is Right But Growth Is Lacking

Does Bliss GVS Pharma (NSE:BLISSGVS) Have A Healthy Balance Sheet?

Feb 20
Does Bliss GVS Pharma (NSE:BLISSGVS) Have A Healthy Balance Sheet?

There Is A Reason Bliss GVS Pharma Limited's (NSE:BLISSGVS) Price Is Undemanding

Jan 26
There Is A Reason Bliss GVS Pharma Limited's (NSE:BLISSGVS) Price Is Undemanding

Does Bliss GVS Pharma (NSE:BLISSGVS) Have A Healthy Balance Sheet?

Jul 14
Does Bliss GVS Pharma (NSE:BLISSGVS) Have A Healthy Balance Sheet?

Bliss GVS Pharma (NSE:BLISSGVS) Has Affirmed Its Dividend Of ₹0.50

Sep 11
Bliss GVS Pharma (NSE:BLISSGVS) Has Affirmed Its Dividend Of ₹0.50

Bliss GVS Pharma (NSE:BLISSGVS) Is Due To Pay A Dividend Of ₹0.50

Aug 28
Bliss GVS Pharma (NSE:BLISSGVS) Is Due To Pay A Dividend Of ₹0.50

These 4 Measures Indicate That Bliss GVS Pharma (NSE:BLISSGVS) Is Using Debt Reasonably Well

May 21
These 4 Measures Indicate That Bliss GVS Pharma (NSE:BLISSGVS) Is Using Debt Reasonably Well

Estimating The Intrinsic Value Of Bliss GVS Pharma Limited (NSE:BLISSGVS)

Apr 08
Estimating The Intrinsic Value Of Bliss GVS Pharma Limited (NSE:BLISSGVS)

A Look At Bliss GVS Pharma's (NSE:BLISSGVS) Share Price Returns

Mar 18
A Look At Bliss GVS Pharma's (NSE:BLISSGVS) Share Price Returns

Here's How We Evaluate Bliss GVS Pharma Limited's (NSE:BLISSGVS) Dividend

Feb 25
Here's How We Evaluate Bliss GVS Pharma Limited's (NSE:BLISSGVS) Dividend

Bliss GVS Pharma (NSE:BLISSGVS) Has A Pretty Healthy Balance Sheet

Feb 08
Bliss GVS Pharma (NSE:BLISSGVS) Has A Pretty Healthy Balance Sheet

What Type Of Shareholders Make Up Bliss GVS Pharma Limited's (NSE:BLISSGVS) Share Registry?

Jan 21
What Type Of Shareholders Make Up Bliss GVS Pharma Limited's (NSE:BLISSGVS) Share Registry?

Do Its Financials Have Any Role To Play In Driving Bliss GVS Pharma Limited's (NSE:BLISSGVS) Stock Up Recently?

Jan 08
Do Its Financials Have Any Role To Play In Driving Bliss GVS Pharma Limited's (NSE:BLISSGVS) Stock Up Recently?

How Is Bliss GVS Pharma's (NSE:BLISSGVS) CEO Paid Relative To Peers?

Dec 26
How Is Bliss GVS Pharma's (NSE:BLISSGVS) CEO Paid Relative To Peers?

Did Bliss GVS Pharma's (NSE:BLISSGVS) Share Price Deserve to Gain 14%?

Dec 13
Did Bliss GVS Pharma's (NSE:BLISSGVS) Share Price Deserve to Gain 14%?

CEO Compensation Analysis

How has Gagan Sharma's remuneration changed compared to Bliss GVS Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024n/an/a

₹596m

Sep 30 2024n/an/a

₹634m

Jun 30 2024n/an/a

₹815m

Mar 31 2024₹22m₹22m

₹755m

Dec 31 2023n/an/a

₹879m

Sep 30 2023n/an/a

₹883m

Jun 30 2023n/an/a

₹598m

Mar 31 2023₹18m₹18m

₹709m

Dec 31 2022n/an/a

₹871m

Sep 30 2022n/an/a

₹91m

Jun 30 2022n/an/a

₹165m

Mar 31 2022₹15m₹15m

₹150m

Dec 31 2021n/an/a

₹17m

Sep 30 2021n/an/a

₹773m

Jun 30 2021n/an/a

₹766m

Mar 31 2021₹1m₹1m

₹685m

Compensation vs Market: Gagan's total compensation ($USD249.83K) is above average for companies of similar size in the Indian market ($USD190.40K).

Compensation vs Earnings: Gagan's compensation has been consistent with company performance over the past year.

CEO

Gagan Sharma (41 yo)

3.7yrs

Tenure

₹21,639,379

Compensation

Mr. Gagan Harsh Sharma serves as Managing Director at Bliss GVS Pharma Limited since May 11, 2021 and its Director since January 21, 2021. He served as Vice President of Strategy and Business Development a...

Leadership Team

NamePositionTenureCompensationOwnership
Gagan Sharma
MD & Director3.7yrs₹21.64mno data
Deepak Sawant
Chief Financial Officer2.1yrs₹6.48mno data
Aditi Bhatt
Compliance Officer6.4yrs₹1.84mno data
Shruti Vishal Rao
Executive & Whole Time Directorno data₹7.41m2%
₹ 330.3m
Prashant Churi
Vice President of Technical Operationsno datano datano data
Vibha Sharma
Executive & Whole Time Directorno data₹7.05m2.35%
₹ 387.5m
Sourya Das
Associate Vice Presidentno datano datano data

3.7yrs

Average Tenure

41yo

Average Age

Experienced Management: BLISSGVS's management team is considered experienced (3.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Gagan Sharma
MD & Director4yrs₹21.64mno data
Shruti Vishal Rao
Executive & Whole Time Director18.5yrs₹7.41m2%
₹ 330.3m
Vibha Sharma
Executive & Whole Time Director16.5yrs₹7.05m2.35%
₹ 387.5m
Shilpa Bhatia
Independent Women Director4.9yrs₹375.00kno data
Santosh Parab
Independent Non-Executive Director8.7yrs₹375.00kno data
Nandkumar Chodankar
Non-Executive Independent Chairmanless than a yearno datano data

6.8yrs

Average Tenure

45.5yo

Average Age

Experienced Board: BLISSGVS's board of directors are considered experienced (6.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 18:18
End of Day Share Price 2025/01/30 00:00
Earnings2024/12/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bliss GVS Pharma Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kameswari V. S. ChavaliFirstCall Research
Anil BurraFirstCall Research